Inhibition of tigar increases exogenous p53 and cisplatin combination sensitivity in lung cancer cells by regulating glycolytic flux

HIGHLIGHTS

• who: Jiaying Fu and collaborators from the Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, China have published the paper: Inhibition of TIGAR Increases Exogenous p53 and Cisplatin Combination Sensitivity in Lung Cancer Cells by Regulating Glycolytic Flux, in the Journal: (JOURNAL)
• how: The authors performed the same treatment in the 16HBE cell lines of bronchial epithelial_cells and the flow cytometry results showed that compared with the cisplatin treatment the combination treatment of p53 and cisplatin did not cause a further apoptosis of the 16HBE cells . To investigate the pathway through which . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.